Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells
Phase 1Active 1 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
High-grade Glioma
Conditions
High-grade Glioma
Trial Timeline
Mar 18, 2025 → Dec 1, 2045
NCT ID
NCT06946680About Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells
Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells is a phase 1 stage product being developed by Brain Biotech for High-grade Glioma. The current trial status is active. This product is registered under clinical trial identifier NCT06946680. Target conditions include High-grade Glioma.
Hype Score Breakdown
Clinical
6
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06946680 | Phase 1 | Active |
Competing Products
8 competing products in High-grade Glioma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| azenosertib | Zentalis Pharmaceuticals | Phase 2 | 32 |
| Sepantronium Bromide | Cothera Bioscience | Phase 2 | 29 |
| Mirvetuximab Soravtansine | AbbVie | Phase 2 | 42 |
| Pembrolizumab + Paclitaxel + Carboplatin + Avastin + MK-4830 + Docetaxel | Merck | Phase 2 | 35 |
| BMS-986463 | Bristol Myers Squibb | Phase 1 | 36 |
| Mebendazole | Brain Biotech | Phase 1 | 19 |
| APR-246 + Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | Aprea Therapeutics | Phase 1/2 | 22 |
| APR-246 + Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | Aprea Therapeutics | Phase 2 | 25 |